首页 > 最新文献

Journal of Pathology Informatics最新文献

英文 中文
Smartphone-based machine learning model for real-time assessment of medical kidney biopsy 基于智能手机的机器学习模型用于医学肾活检的实时评估
Q2 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jpi.2024.100385
Odianosen J. Eigbire-Molen , Clarissa A. Cassol , Daniel J. Kenan , Johnathan O.H. Napier , Lyle J. Burdine , Shana M. Coley , Shree G. Sharma

Background

Kidney biopsy is the gold-standard for diagnosing medical renal diseases, but the accuracy of the diagnosis greatly depends on the quality of the biopsy specimen, particularly the amount of renal cortex obtained. Inadequate biopsies, characterized by insufficient cortex or predominant medulla, can lead to inconclusive or incorrect diagnoses, and repeat biopsy. Unfortunately, there has been a concerning increase in the rate of inadequate kidney biopsies, and not all medical centers have access to trained professionals who can assess biopsy adequacy in real time. In response to this challenge, we aimed to develop a machine learning model capable of assessing the percentage cortex of each biopsy pass using smartphone images of the kidney biopsy tissue at the time of biopsy.

Methods

747 kidney biopsy cores and corresponding smartphone macro images were collected from five unused deceased donor kidneys. Each core was imaged, formalin-fixed, sectioned, and stained with Periodic acid–Schiff (PAS) to determine cortex percentage. The fresh unfixed core images were captured using the macro camera on an iPhone 13 Pro. Two experienced renal pathologists independently reviewed the PAS-stained sections to determine the cortex percentage. For the purpose of this study, the biopsies with less than 30% cortex were labeled as inadequate, while those with 30% or more cortex were classified as adequate. The dataset was divided into training (n=643), validation (n=30), and test (n=74) sets. Preprocessing steps involved converting High-Efficiency Image Container iPhone format images to JPEG, normalization, and renal tissue segmentation using a U-Net deep learning model. Subsequently, a classification deep learning model was trained on the renal tissue region of interest and corresponding class label.

Results

The deep learning model achieved an accuracy of 85% on the training data. On the independent test dataset, the model exhibited an accuracy of 81%. For inadequate samples in the test dataset, the model showed a sensitivity of 71%, suggesting its capability to identify cases with inadequate cortical representation. The area under the receiver-operating curve (AUC-ROC) on the test dataset was 0.80.

Conclusion

We successfully developed and tested a machine learning model for classifying smartphone images of kidney biopsies as either adequate or inadequate, based on the amount of cortex determined by expert renal pathologists. The model's promising results suggest its potential as a smartphone application to assist real-time assessment of kidney biopsy tissue, particularly in settings with limited access to trained personnel. Further refinements and validations are warranted to optimize the model's performance.

背景肾活检是诊断内科肾脏疾病的金标准,但诊断的准确性在很大程度上取决于活检标本的质量,尤其是获得的肾皮质的数量。活检不充分,表现为皮质不足或髓质占优势,可导致诊断不确定或不正确,并导致重复活检。遗憾的是,肾脏活检不充分的比例一直在上升,而且并非所有医疗中心都有训练有素的专业人员来实时评估活检是否充分。为了应对这一挑战,我们旨在开发一种机器学习模型,该模型能够利用活检时肾脏活检组织的智能手机图像评估每次活检的皮质百分比。每个肾芯都经过成像、福尔马林固定、切片和过硫酸希夫(PAS)染色,以确定皮质百分比。使用 iPhone 13 Pro 的微距摄像头拍摄了新鲜的未固定肾芯图像。两名经验丰富的肾脏病理学家独立审查 PAS 染色切片,以确定皮质百分比。在本研究中,皮质少于 30% 的活检样本被标记为皮质不足,而皮质达到或超过 30% 的活检样本则被归类为皮质充足。数据集分为训练集(样本数=643)、验证集(样本数=30)和测试集(样本数=74)。预处理步骤包括将高效图像容器 iPhone 格式图像转换为 JPEG、归一化,以及使用 U-Net 深度学习模型进行肾组织分割。随后,根据感兴趣的肾组织区域和相应的类标签训练分类深度学习模型。在独立测试数据集上,该模型的准确率为 81%。对于测试数据集中的不足样本,该模型显示出 71% 的灵敏度,表明它有能力识别皮质表征不足的病例。结论我们成功开发并测试了一种机器学习模型,该模型可根据肾脏病理专家确定的皮质数量,将肾脏活检的智能手机图像分类为充分或不充分。该模型取得了令人鼓舞的结果,表明它有潜力作为智能手机应用来协助实时评估肾活检组织,尤其是在训练有素的人员有限的情况下。为了优化该模型的性能,还需要进一步的改进和验证。
{"title":"Smartphone-based machine learning model for real-time assessment of medical kidney biopsy","authors":"Odianosen J. Eigbire-Molen ,&nbsp;Clarissa A. Cassol ,&nbsp;Daniel J. Kenan ,&nbsp;Johnathan O.H. Napier ,&nbsp;Lyle J. Burdine ,&nbsp;Shana M. Coley ,&nbsp;Shree G. Sharma","doi":"10.1016/j.jpi.2024.100385","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100385","url":null,"abstract":"<div><h3>Background</h3><p>Kidney biopsy is the gold-standard for diagnosing medical renal diseases, but the accuracy of the diagnosis greatly depends on the quality of the biopsy specimen, particularly the amount of renal cortex obtained. Inadequate biopsies, characterized by insufficient cortex or predominant medulla, can lead to inconclusive or incorrect diagnoses, and repeat biopsy. Unfortunately, there has been a concerning increase in the rate of inadequate kidney biopsies, and not all medical centers have access to trained professionals who can assess biopsy adequacy in real time. In response to this challenge, we aimed to develop a machine learning model capable of assessing the percentage cortex of each biopsy pass using smartphone images of the kidney biopsy tissue at the time of biopsy.</p></div><div><h3>Methods</h3><p>747 kidney biopsy cores and corresponding smartphone macro images were collected from five unused deceased donor kidneys. Each core was imaged, formalin-fixed, sectioned, and stained with Periodic acid–Schiff (PAS) to determine cortex percentage. The fresh unfixed core images were captured using the macro camera on an iPhone 13 Pro. Two experienced renal pathologists independently reviewed the PAS-stained sections to determine the cortex percentage. For the purpose of this study, the biopsies with less than 30% cortex were labeled as inadequate, while those with 30% or more cortex were classified as adequate. The dataset was divided into training (<em>n</em>=643), validation (<em>n</em>=30), and test (<em>n</em>=74) sets. Preprocessing steps involved converting High-Efficiency Image Container iPhone format images to JPEG, normalization, and renal tissue segmentation using a U-Net deep learning model. Subsequently, a classification deep learning model was trained on the renal tissue region of interest and corresponding class label.</p></div><div><h3>Results</h3><p>The deep learning model achieved an accuracy of 85% on the training data. On the independent test dataset, the model exhibited an accuracy of 81%. For inadequate samples in the test dataset, the model showed a sensitivity of 71%, suggesting its capability to identify cases with inadequate cortical representation. The area under the receiver-operating curve (AUC-ROC) on the test dataset was 0.80.</p></div><div><h3>Conclusion</h3><p>We successfully developed and tested a machine learning model for classifying smartphone images of kidney biopsies as either adequate or inadequate, based on the amount of cortex determined by expert renal pathologists. The model's promising results suggest its potential as a smartphone application to assist real-time assessment of kidney biopsy tissue, particularly in settings with limited access to trained personnel. Further refinements and validations are warranted to optimize the model's performance.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100385"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000245/pdfft?md5=aa0cdf6fbf647b60d197599f7a7fc32d&pid=1-s2.0-S2153353924000245-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141541797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Joining forces for pathology diagnostics with AI assistance: The EMPAIA initiative 联合起来,利用人工智能辅助病理诊断:EMPAIA 倡议
Q2 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jpi.2024.100387
Norman Zerbe , Lars Ole Schwen , Christian Geißler , Katja Wiesemann , Tom Bisson , Peter Boor , Rita Carvalho , Michael Franz , Christoph Jansen , Tim-Rasmus Kiehl , Björn Lindequist , Nora Charlotte Pohlan , Sarah Schmell , Klaus Strohmenger , Falk Zakrzewski , Markus Plass , Michael Takla , Tobias Küster , André Homeyer , Peter Hufnagl

Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces.

The open and vendor-neutral EMPAIA initiative addresses these challenges. Here, we provide an overview of EMPAIA's achievements and lessons learned. EMPAIA integrates various stakeholders of the pathology AI ecosystem, i.e., pathologists, computer scientists, and industry. In close collaboration, we developed technical interoperability standards, recommendations for AI testing and product development, and explainability methods. We implemented the modular and open-source EMPAIA Platform and successfully integrated 14 AI-based image analysis apps from eight different vendors, demonstrating how different apps can use a single standardized interface. We prioritized requirements and evaluated the use of AI in real clinical settings with 14 different pathology laboratories in Europe and Asia. In addition to technical developments, we created a forum for all stakeholders to share information and experiences on digital pathology and AI. Commercial, clinical, and academic stakeholders can now adopt EMPAIA's common open-source interfaces, providing a unique opportunity for large-scale standardization and streamlining of processes.

Further efforts are needed to effectively and broadly establish AI assistance in routine laboratory use. To this end, a sustainable infrastructure, the non-profit association EMPAIA International, has been established to continue standardization and support broad implementation and advocacy for an AI-assisted digital pathology future.

过去十年间,病理学领域的人工智能(AI)方法取得了长足的进步。然而,由于面临诸多挑战,包括将研究成果转化为临床诊断产品的技术和监管障碍,以及缺乏标准化接口等,将人工智能方法融入常规临床实践的进程十分缓慢。在此,我们将概述 EMPAIA 的成就和经验教训。EMPAIA 整合了病理人工智能生态系统的各利益相关方,即病理学家、计算机科学家和业界。通过密切合作,我们制定了技术互操作性标准、人工智能测试和产品开发建议以及可解释性方法。我们实施了模块化和开源的 EMPAIA 平台,并成功集成了来自 8 个不同供应商的 14 个基于人工智能的图像分析应用程序,展示了不同应用程序如何使用单一的标准化界面。我们对需求进行了优先排序,并与欧洲和亚洲的 14 家不同病理实验室一起评估了人工智能在实际临床环境中的应用。除了技术开发,我们还为所有利益相关者创建了一个论坛,以分享数字病理学和人工智能方面的信息和经验。商业、临床和学术利益相关者现在可以采用EMPAIA的通用开源接口,为大规模标准化和简化流程提供了一个独特的机会。为此,我们建立了一个可持续的基础设施,即非营利性协会 EMPAIA 国际,以继续实现标准化并支持广泛实施和宣传人工智能辅助数字病理学的未来。
{"title":"Joining forces for pathology diagnostics with AI assistance: The EMPAIA initiative","authors":"Norman Zerbe ,&nbsp;Lars Ole Schwen ,&nbsp;Christian Geißler ,&nbsp;Katja Wiesemann ,&nbsp;Tom Bisson ,&nbsp;Peter Boor ,&nbsp;Rita Carvalho ,&nbsp;Michael Franz ,&nbsp;Christoph Jansen ,&nbsp;Tim-Rasmus Kiehl ,&nbsp;Björn Lindequist ,&nbsp;Nora Charlotte Pohlan ,&nbsp;Sarah Schmell ,&nbsp;Klaus Strohmenger ,&nbsp;Falk Zakrzewski ,&nbsp;Markus Plass ,&nbsp;Michael Takla ,&nbsp;Tobias Küster ,&nbsp;André Homeyer ,&nbsp;Peter Hufnagl","doi":"10.1016/j.jpi.2024.100387","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100387","url":null,"abstract":"<div><p>Over the past decade, artificial intelligence (AI) methods in pathology have advanced substantially. However, integration into routine clinical practice has been slow due to numerous challenges, including technical and regulatory hurdles in translating research results into clinical diagnostic products and the lack of standardized interfaces.</p><p>The open and vendor-neutral EMPAIA initiative addresses these challenges. Here, we provide an overview of EMPAIA's achievements and lessons learned. EMPAIA integrates various stakeholders of the pathology AI ecosystem, i.e., pathologists, computer scientists, and industry. In close collaboration, we developed technical interoperability standards, recommendations for AI testing and product development, and explainability methods. We implemented the modular and open-source EMPAIA Platform and successfully integrated 14 AI-based image analysis apps from eight different vendors, demonstrating how different apps can use a single standardized interface. We prioritized requirements and evaluated the use of AI in real clinical settings with 14 different pathology laboratories in Europe and Asia. In addition to technical developments, we created a forum for all stakeholders to share information and experiences on digital pathology and AI. Commercial, clinical, and academic stakeholders can now adopt EMPAIA's common open-source interfaces, providing a unique opportunity for large-scale standardization and streamlining of processes.</p><p>Further efforts are needed to effectively and broadly establish AI assistance in routine laboratory use. To this end, a sustainable infrastructure, the non-profit association EMPAIA International, has been established to continue standardization and support broad implementation and advocacy for an AI-assisted digital pathology future.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100387"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000269/pdfft?md5=93cff7c5dd94e55a015f5beb1d21f7eb&pid=1-s2.0-S2153353924000269-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel Slide-seq based image processing software to identify gene expression at the single cell level 基于 Slide-seq 图像处理软件的新型单细胞基因表达鉴定软件
Q2 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jpi.2024.100384
Th.I. Götz , X. Cong , S. Rauber , M. Angeli , E.W. Lang , A. Ramming , C. Schmidkonz

Analysis of gene expression at the single-cell level could help predict the effectiveness of therapies in the field of chronic inflammatory diseases such as arthritis. Here, we demonstrate an adopted approach for processing images from the Slide-seq method. Using a puck, which consists of about 50,000 DNA barcode beads, an RNA sequence of a cell is to be read. The pucks are repeatedly brought into contact with liquids and then recorded with a conventional epifluorescence microscope. The image analysis initially consists of stitching the partial images of a sequence recording, registering images from different sequences, and finally reading out the bases. The new method enables the use of an inexpensive epifluorescence microscope instead of a confocal microscope.

单细胞水平的基因表达分析有助于预测关节炎等慢性炎症性疾病的治疗效果。在这里,我们展示了一种采用 Slide-seq 方法处理图像的方法。使用由大约 50,000 个 DNA 条形码珠组成的小球,可以读取细胞的 RNA 序列。小球反复与液体接触,然后用传统的荧光显微镜进行记录。图像分析最初包括拼接序列记录的部分图像、登记不同序列的图像以及最终读出碱基。这种新方法可以使用廉价的外荧光显微镜代替共聚焦显微镜。
{"title":"A novel Slide-seq based image processing software to identify gene expression at the single cell level","authors":"Th.I. Götz ,&nbsp;X. Cong ,&nbsp;S. Rauber ,&nbsp;M. Angeli ,&nbsp;E.W. Lang ,&nbsp;A. Ramming ,&nbsp;C. Schmidkonz","doi":"10.1016/j.jpi.2024.100384","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100384","url":null,"abstract":"<div><p>Analysis of gene expression at the single-cell level could help predict the effectiveness of therapies in the field of chronic inflammatory diseases such as arthritis. Here, we demonstrate an adopted approach for processing images from the Slide-seq method. Using a puck, which consists of about 50,000 DNA barcode beads, an RNA sequence of a cell is to be read. The pucks are repeatedly brought into contact with liquids and then recorded with a conventional epifluorescence microscope. The image analysis initially consists of stitching the partial images of a sequence recording, registering images from different sequences, and finally reading out the bases. The new method enables the use of an inexpensive epifluorescence microscope instead of a confocal microscope.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100384"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000233/pdfft?md5=4839c565f8920eeea61c5ef01d5bb248&pid=1-s2.0-S2153353924000233-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eye tracking in digital pathology: A comprehensive literature review 数字病理学中的眼动仪:综合文献综述
Q2 Medicine Pub Date : 2024-05-17 DOI: 10.1016/j.jpi.2024.100383
Alana Lopes , Aaron D. Ward , Matthew Cecchini

Eye tracking has been used for decades in attempt to understand the cognitive processes of individuals. From memory access to problem-solving to decision-making, such insight has the potential to improve workflows and the education of students to become experts in relevant fields. Until recently, the traditional use of microscopes in pathology made eye tracking exceptionally difficult. However, the digital revolution of pathology from conventional microscopes to digital whole slide images allows for new research to be conducted and information to be learned with regards to pathologist visual search patterns and learning experiences. This has the promise to make pathology education more efficient and engaging, ultimately creating stronger and more proficient generations of pathologists to come. The goal of this review on eye tracking in pathology is to characterize and compare the visual search patterns of pathologists. The PubMed and Web of Science databases were searched using ‘pathology’ AND ‘eye tracking’ synonyms. A total of 22 relevant full-text articles published up to and including 2023 were identified and included in this review. Thematic analysis was conducted to organize each study into one or more of the 10 themes identified to characterize the visual search patterns of pathologists: (1) effect of experience, (2) fixations, (3) zooming, (4) panning, (5) saccades, (6) pupil diameter, (7) interpretation time, (8) strategies, (9) machine learning, and (10) education. Expert pathologists were found to have higher diagnostic accuracy, fewer fixations, and shorter interpretation times than pathologists with less experience. Further, literature on eye tracking in pathology indicates that there are several visual strategies for diagnostic interpretation of digital pathology images, but no evidence of a superior strategy exists. The educational implications of eye tracking in pathology have also been explored but the effect of teaching novices how to search as an expert remains unclear. In this article, the main challenges and prospects of eye tracking in pathology are briefly discussed along with their implications to the field.

几十年来,人们一直在使用眼动仪试图了解个人的认知过程。从获取记忆到解决问题再到决策,这种洞察力有可能改进工作流程和学生教育,使其成为相关领域的专家。直到最近,病理学中显微镜的传统使用还使得眼球跟踪异常困难。然而,病理学从传统显微镜到全玻片数字图像的数字化革命,使病理学家的视觉搜索模式和学习经验方面的新研究和新信息得以开展。这有望提高病理学教育的效率和吸引力,最终培养出更强大、更精通的新一代病理学家。这篇关于病理学眼动追踪的综述旨在描述和比较病理学家的视觉搜索模式。我们使用 "病理学 "和 "眼动仪 "同义词在 PubMed 和 Web of Science 数据库中进行了搜索。共找到 22 篇截至 2023 年(含 2023 年)发表的相关全文文章,并将其纳入本综述。我们对每篇研究进行了主题分析,将其归纳为 10 个主题中的一个或多个,以描述病理学家的视觉搜索模式:(1) 经验的影响;(2) 固定;(3) 缩放;(4) 平移;(5) 囊视;(6) 瞳孔直径;(7) 解释时间;(8) 策略;(9) 机器学习;(10) 教育。研究发现,与经验较少的病理学家相比,专家级病理学家的诊断准确率更高、定点次数更少、判读时间更短。此外,有关病理学眼动追踪的文献表明,有几种视觉策略可用于数字病理图像的诊断解读,但没有证据表明存在一种更优越的策略。也有人探讨了眼动追踪在病理学中的教育意义,但教导新手如何像专家一样进行搜索的效果仍不明确。本文简要讨论了眼动追踪技术在病理学领域的主要挑战和前景,以及对该领域的影响。
{"title":"Eye tracking in digital pathology: A comprehensive literature review","authors":"Alana Lopes ,&nbsp;Aaron D. Ward ,&nbsp;Matthew Cecchini","doi":"10.1016/j.jpi.2024.100383","DOIUrl":"10.1016/j.jpi.2024.100383","url":null,"abstract":"<div><p>Eye tracking has been used for decades in attempt to understand the cognitive processes of individuals. From memory access to problem-solving to decision-making, such insight has the potential to improve workflows and the education of students to become experts in relevant fields. Until recently, the traditional use of microscopes in pathology made eye tracking exceptionally difficult. However, the digital revolution of pathology from conventional microscopes to digital whole slide images allows for new research to be conducted and information to be learned with regards to pathologist visual search patterns and learning experiences. This has the promise to make pathology education more efficient and engaging, ultimately creating stronger and more proficient generations of pathologists to come. The goal of this review on eye tracking in pathology is to characterize and compare the visual search patterns of pathologists. The PubMed and Web of Science databases were searched using ‘pathology’ AND ‘eye tracking’ synonyms. A total of 22 relevant full-text articles published up to and including 2023 were identified and included in this review. Thematic analysis was conducted to organize each study into one or more of the 10 themes identified to characterize the visual search patterns of pathologists: (1) effect of experience, (2) fixations, (3) zooming, (4) panning, (5) saccades, (6) pupil diameter, (7) interpretation time, (8) strategies, (9) machine learning, and (10) education. Expert pathologists were found to have higher diagnostic accuracy, fewer fixations, and shorter interpretation times than pathologists with less experience. Further, literature on eye tracking in pathology indicates that there are several visual strategies for diagnostic interpretation of digital pathology images, but no evidence of a superior strategy exists. The educational implications of eye tracking in pathology have also been explored but the effect of teaching novices how to search as an expert remains unclear. In this article, the main challenges and prospects of eye tracking in pathology are briefly discussed along with their implications to the field.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100383"},"PeriodicalIF":0.0,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000221/pdfft?md5=01458aa9d7539a3f8a155a98d18ad8ba&pid=1-s2.0-S2153353924000221-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141024415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CDK: A novel high-performance transfer feature technique for early detection of osteoarthritis CDK:用于早期检测骨关节炎的新型高性能转移特征技术
Q2 Medicine Pub Date : 2024-05-08 DOI: 10.1016/j.jpi.2024.100382
Mohammad Shariful Islam , Mohammad Abu Tareq Rony

Knee osteoarthritis (OA) is a prevalent condition causing significant disability, particularly among the elderly, necessitating advancements in diagnostic methodologies to facilitate early detection and treatment. Traditional OA diagnosis, relying on radiography and physical exams, faces limitations in accuracy and objectivity. This underscores the need for more advanced diagnostic methods, such as machine learning (ML) and deep learning (DL), to improve OA detection and classification. This research introduces a novel ensemble learning approach for image data feature extraction which ingeniously combines the strengths of 2 advanced (ML) models with a (DL) method to substantially improve the accuracy of OA detection from radiographic images. This innovative strategy aims to address the limitations of traditional diagnostic tools by leveraging the enhanced sensitivity and specificity of combined ML and DL models. The methodology deployed in this study encompasses the application of 10 ML models to a comprehensive publicly available Kaggle dataset with a total of 3615 samples of knee X-ray images. Through rigorous k-fold cross-validation and meticulous hyperparameter optimization, we also included evaluation metrics like accuracy, receiver operating characteristic, precision, recall, and F1-score to assess our models' performance effectively. The proposed novel CDK (convolutional neural network, decision tree, K-nearest classifier) ensemble approach for feature extraction is designed to synergize the predictive capabilities of individual models, thereby significantly improving the detection accuracy of OA indicators within radiographic images. We applied several ML and DL approaches to the newly created feature set to evaluate performance. The CDK ensemble model outperformed state-of-the-art studies with a high-performance score of 99.72% accuracy. This remarkable achievement underscores the model's exceptional capability in the early detection of OA, highlighting its superiority in comparison to existing methods.

膝关节骨关节炎(OA)是一种导致严重残疾的常见疾病,尤其是在老年人中,因此有必要改进诊断方法,以便及早发现和治疗。传统的 OA 诊断依赖于射线照相和体格检查,在准确性和客观性方面存在局限性。这凸显了对更先进诊断方法的需求,如机器学习(ML)和深度学习(DL),以改善 OA 检测和分类。本研究介绍了一种用于图像数据特征提取的新型集合学习方法,该方法巧妙地结合了两种先进(ML)模型和一种(DL)方法的优势,从而大幅提高了从放射图像中检测 OA 的准确性。这一创新策略旨在利用 ML 和 DL 组合模型增强的灵敏度和特异性,解决传统诊断工具的局限性。本研究采用的方法包括将 10 个 ML 模型应用于一个全面的公开 Kaggle 数据集,该数据集共有 3615 个膝关节 X 光图像样本。通过严格的 k 倍交叉验证和细致的超参数优化,我们还纳入了准确率、接收者操作特征、精确度、召回率和 F1 分数等评价指标,以有效评估模型的性能。我们提出的新型 CDK(卷积神经网络、决策树、K-最近分类器)特征提取集合方法旨在协同各个模型的预测能力,从而显著提高放射影像中 OA 指标的检测准确率。我们对新创建的特征集采用了多种 ML 和 DL 方法来评估性能。CDK 组合模型的准确率高达 99.72%,超过了最先进的研究结果。这一骄人成绩彰显了该模型在早期检测 OA 方面的卓越能力,突出了它与现有方法相比的优越性。
{"title":"CDK: A novel high-performance transfer feature technique for early detection of osteoarthritis","authors":"Mohammad Shariful Islam ,&nbsp;Mohammad Abu Tareq Rony","doi":"10.1016/j.jpi.2024.100382","DOIUrl":"10.1016/j.jpi.2024.100382","url":null,"abstract":"<div><p>Knee osteoarthritis (OA) is a prevalent condition causing significant disability, particularly among the elderly, necessitating advancements in diagnostic methodologies to facilitate early detection and treatment. Traditional OA diagnosis, relying on radiography and physical exams, faces limitations in accuracy and objectivity. This underscores the need for more advanced diagnostic methods, such as machine learning (ML) and deep learning (DL), to improve OA detection and classification. This research introduces a novel ensemble learning approach for image data feature extraction which ingeniously combines the strengths of 2 advanced (ML) models with a (DL) method to substantially improve the accuracy of OA detection from radiographic images. This innovative strategy aims to address the limitations of traditional diagnostic tools by leveraging the enhanced sensitivity and specificity of combined ML and DL models. The methodology deployed in this study encompasses the application of 10 ML models to a comprehensive publicly available Kaggle dataset with a total of 3615 samples of knee X-ray images. Through rigorous k-fold cross-validation and meticulous hyperparameter optimization, we also included evaluation metrics like accuracy, receiver operating characteristic, precision, recall, and F1-score to assess our models' performance effectively. The proposed novel CDK (convolutional neural network, decision tree, K-nearest classifier) ensemble approach for feature extraction is designed to synergize the predictive capabilities of individual models, thereby significantly improving the detection accuracy of OA indicators within radiographic images. We applied several ML and DL approaches to the newly created feature set to evaluate performance. The CDK ensemble model outperformed state-of-the-art studies with a high-performance score of 99.72% accuracy. This remarkable achievement underscores the model's exceptional capability in the early detection of OA, highlighting its superiority in comparison to existing methods.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100382"},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S215335392400021X/pdfft?md5=7758136ea8b6ff5e5d21a4755ae40c6d&pid=1-s2.0-S215335392400021X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141028032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer 选择性 CutMix 方法提高了基于深度学习的前列腺癌分级和风险评估的普适性
Q2 Medicine Pub Date : 2024-05-07 DOI: 10.1016/j.jpi.2024.100381
Sushant Patkar , Stephanie Harmon , Isabell Sesterhenn , Rosina Lis , Maria Merino , Denise Young , G. Thomas Brown , Kimberly M. Greenfield , John D. McGeeney , Sally Elsamanoudi , Shyh-Han Tan , Cara Schafer , Jiji Jiang , Gyorgy Petrovics , Albert Dobi , Francisco J. Rentas , Peter A. Pinto , Gregory T. Chesnut , Peter Choyke , Baris Turkbey , Joel T. Moncur

The Gleason score is an important predictor of prognosis in prostate cancer. However, its subjective nature can result in over- or under-grading. Our objective was to train an artificial intelligence (AI)-based algorithm to grade prostate cancer in specimens from patients who underwent radical prostatectomy (RP) and to assess the correlation of AI-estimated proportions of different Gleason patterns with biochemical recurrence-free survival (RFS), metastasis-free survival (MFS), and overall survival (OS). Training and validation of algorithms for cancer detection and grading were completed with three large datasets containing a total of 580 whole-mount prostate slides from 191 RP patients at two centers and 6218 annotated needle biopsy slides from the publicly available Prostate Cancer Grading Assessment dataset. A cancer detection model was trained using MobileNetV3 on 0.5 mm × 0.5 mm cancer areas (tiles) captured at 10× magnification. For cancer grading, a Gleason pattern detector was trained on tiles using a ResNet50 convolutional neural network and a selective CutMix training strategy involving a mixture of real and artificial examples. This strategy resulted in improved model generalizability in the test set compared with three different control experiments when evaluated on both needle biopsy slides and whole-mount prostate slides from different centers. In an additional test cohort of RP patients who were clinically followed over 30 years, quantitative Gleason pattern AI estimates achieved concordance indexes of 0.69, 0.72, and 0.64 for predicting RFS, MFS, and OS times, outperforming the control experiments and International Society of Urological Pathology system (ISUP) grading by pathologists. Finally, unsupervised clustering of test RP patient specimens into low-, medium-, and high-risk groups based on AI-estimated proportions of each Gleason pattern resulted in significantly improved RFS and MFS stratification compared with ISUP grading. In summary, deep learning-based quantitative Gleason scoring using a selective CutMix training strategy may improve prognostication after prostate cancer surgery.

格里森评分是预测前列腺癌预后的重要指标。然而,其主观性可能导致评分过高或过低。我们的目标是训练一种基于人工智能(AI)的算法,对接受根治性前列腺切除术(RP)患者标本中的前列腺癌进行分级,并评估人工智能估计的不同Gleason模式比例与无生化复发生存期(RFS)、无转移生存期(MFS)和总生存期(OS)之间的相关性。利用三个大型数据集完成了癌症检测和分级算法的训练和验证,这三个数据集包含来自两个中心 191 名前列腺癌患者的共 580 张全切前列腺切片,以及来自公开的前列腺癌分级评估数据集的 6218 张带注释的针刺活检切片。使用 MobileNetV3 对以 10 倍放大率捕获的 0.5 mm × 0.5 mm 癌症区域(瓦片)进行了癌症检测模型训练。在癌症分级方面,使用 ResNet50 卷积神经网络和选择性 CutMix 训练策略(包括真实和人工示例的混合)在瓷砖上训练格里森模式检测器。在对来自不同中心的针刺活检切片和全装前列腺切片进行评估时,与三个不同的对照实验相比,这种策略提高了模型在测试集中的通用性。在对临床随访超过 30 年的前列腺癌患者进行的另一个测试组中,定量格里森模式 AI 估计值在预测 RFS、MFS 和 OS 时间方面的一致性指数分别为 0.69、0.72 和 0.64,优于对照实验和国际泌尿病理学会病理学家分级系统(ISUP)。最后,与 ISUP 分级相比,根据人工智能估计的每种 Gleason 模式的比例将测试 RP 患者标本无监督聚类为低、中、高风险组,可显著改善 RFS 和 MFS 分层。总之,使用选择性 CutMix 训练策略进行基于深度学习的定量格里森评分可以改善前列腺癌手术后的预后。
{"title":"A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer","authors":"Sushant Patkar ,&nbsp;Stephanie Harmon ,&nbsp;Isabell Sesterhenn ,&nbsp;Rosina Lis ,&nbsp;Maria Merino ,&nbsp;Denise Young ,&nbsp;G. Thomas Brown ,&nbsp;Kimberly M. Greenfield ,&nbsp;John D. McGeeney ,&nbsp;Sally Elsamanoudi ,&nbsp;Shyh-Han Tan ,&nbsp;Cara Schafer ,&nbsp;Jiji Jiang ,&nbsp;Gyorgy Petrovics ,&nbsp;Albert Dobi ,&nbsp;Francisco J. Rentas ,&nbsp;Peter A. Pinto ,&nbsp;Gregory T. Chesnut ,&nbsp;Peter Choyke ,&nbsp;Baris Turkbey ,&nbsp;Joel T. Moncur","doi":"10.1016/j.jpi.2024.100381","DOIUrl":"10.1016/j.jpi.2024.100381","url":null,"abstract":"<div><p>The Gleason score is an important predictor of prognosis in prostate cancer. However, its subjective nature can result in over- or under-grading. Our objective was to train an artificial intelligence (AI)-based algorithm to grade prostate cancer in specimens from patients who underwent radical prostatectomy (RP) and to assess the correlation of AI-estimated proportions of different Gleason patterns with biochemical recurrence-free survival (RFS), metastasis-free survival (MFS), and overall survival (OS). Training and validation of algorithms for cancer detection and grading were completed with three large datasets containing a total of 580 whole-mount prostate slides from 191 RP patients at two centers and 6218 annotated needle biopsy slides from the publicly available Prostate Cancer Grading Assessment dataset. A cancer detection model was trained using MobileNetV3 on 0.5 mm × 0.5 mm cancer areas (tiles) captured at 10× magnification. For cancer grading, a Gleason pattern detector was trained on tiles using a ResNet50 convolutional neural network and a selective CutMix training strategy involving a mixture of real and artificial examples. This strategy resulted in improved model generalizability in the test set compared with three different control experiments when evaluated on both needle biopsy slides and whole-mount prostate slides from different centers. In an additional test cohort of RP patients who were clinically followed over 30 years, quantitative Gleason pattern AI estimates achieved concordance indexes of 0.69, 0.72, and 0.64 for predicting RFS, MFS, and OS times, outperforming the control experiments and International Society of Urological Pathology system (ISUP) grading by pathologists. Finally, unsupervised clustering of test RP patient specimens into low-, medium-, and high-risk groups based on AI-estimated proportions of each Gleason pattern resulted in significantly improved RFS and MFS stratification compared with ISUP grading. In summary, deep learning-based quantitative Gleason scoring using a selective CutMix training strategy may improve prognostication after prostate cancer surgery.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100381"},"PeriodicalIF":0.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000208/pdfft?md5=3e256673a8f52212fb05001cc4e50f5b&pid=1-s2.0-S2153353924000208-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141042139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis—real-world experience 将人工智能算法作为前列腺癌诊断的第二读取系统的验证和三年临床经验--真实世界的经验
Q2 Medicine Pub Date : 2024-04-30 DOI: 10.1016/j.jpi.2024.100378
Juan Carlos Santa-Rosario, Erik A. Gustafson, Dario E. Sanabria Bellassai, Phillip E. Gustafson, Mariano de Socarraz

Background

Prostate cancer ranks as the most frequently diagnosed cancer in men in the USA, with significant mortality rates. Early detection is pivotal for optimal patient outcomes, providing increased treatment options and potentially less invasive interventions. There remain significant challenges in prostate cancer histopathology, including the potential for missed diagnoses due to pathologist variability and subjective interpretations.

Methods

To address these challenges, this study investigates the ability of artificial intelligence (AI) to enhance diagnostic accuracy. The Galen™ Prostate AI algorithm was validated on a cohort of Puerto Rican men to demonstrate its efficacy in cancer detection and Gleason grading. Subsequently, the AI algorithm was integrated into routine clinical practice during a 3-year period at a CLIA certified precision pathology laboratory.

Results

The Galen™ Prostate AI algorithm showed a 96.7% (95% CI 95.6–97.8) specificity and a 96.6% (95% CI 93.3–98.8) sensitivity for prostate cancer detection and 82.1% specificity (95% CI 73.9–88.5) and 81.1% sensitivity (95% CI 73.7–87.2) for distinction of Gleason Grade Group 1 from Grade Group 2+. The subsequent AI integration into routine clinical use examined prostate cancer diagnoses on >122,000 slides and 9200 cases over 3 years and had an overall AI Impact ™ factor of 1.8%.

Conclusions

The potential of AI to be a powerful, reliable, and effective diagnostic tool for pathologists is highlighted, while the AI Impact™ in a real-world setting demonstrates the ability of AI to standardize prostate cancer diagnosis at a high level of performance across pathologists.

背景在美国,前列腺癌是最常见的男性癌症,死亡率很高。早期检测是获得最佳治疗效果的关键,它提供了更多的治疗选择,并可能减少侵入性干预。前列腺癌组织病理学仍面临重大挑战,包括由于病理学家的变异和主观解释可能导致漏诊。Galen™ 前列腺人工智能算法在一组波多黎各男性中进行了验证,以证明其在癌症检测和格里森分级方面的功效。结果 Galen™ 前列腺 AI 算法在前列腺癌检测方面的特异性为 96.7%(95% CI 95.6-97.8),灵敏度为 96.6%(95% CI 93.3-98.8);在区分格里森 1 级和 2+ 级方面,特异性为 82.1%(95% CI 73.9-88.5),灵敏度为 81.1%(95% CI 73.7-87.2)。结论人工智能作为病理学家强大、可靠和有效的诊断工具的潜力得到了强调,而在真实世界环境中的人工智能影响(AI Impact™)表明,人工智能有能力使病理学家的前列腺癌诊断达到高水平的标准化。
{"title":"Validation and three years of clinical experience in using an artificial intelligence algorithm as a second read system for prostate cancer diagnosis—real-world experience","authors":"Juan Carlos Santa-Rosario,&nbsp;Erik A. Gustafson,&nbsp;Dario E. Sanabria Bellassai,&nbsp;Phillip E. Gustafson,&nbsp;Mariano de Socarraz","doi":"10.1016/j.jpi.2024.100378","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100378","url":null,"abstract":"<div><h3>Background</h3><p>Prostate cancer ranks as the most frequently diagnosed cancer in men in the USA, with significant mortality rates. Early detection is pivotal for optimal patient outcomes, providing increased treatment options and potentially less invasive interventions. There remain significant challenges in prostate cancer histopathology, including the potential for missed diagnoses due to pathologist variability and subjective interpretations.</p></div><div><h3>Methods</h3><p>To address these challenges, this study investigates the ability of artificial intelligence (AI) to enhance diagnostic accuracy. The Galen™ Prostate AI algorithm was validated on a cohort of Puerto Rican men to demonstrate its efficacy in cancer detection and Gleason grading. Subsequently, the AI algorithm was integrated into routine clinical practice during a 3-year period at a CLIA certified precision pathology laboratory.</p></div><div><h3>Results</h3><p>The Galen™ Prostate AI algorithm showed a 96.7% (95% CI 95.6–97.8) specificity and a 96.6% (95% CI 93.3–98.8) sensitivity for prostate cancer detection and 82.1% specificity (95% CI 73.9–88.5) and 81.1% sensitivity (95% CI 73.7–87.2) for distinction of Gleason Grade Group 1 from Grade Group 2+. The subsequent AI integration into routine clinical use examined prostate cancer diagnoses on &gt;122,000 slides and 9200 cases over 3 years and had an overall AI Impact ™ factor of 1.8%.</p></div><div><h3>Conclusions</h3><p>The potential of AI to be a powerful, reliable, and effective diagnostic tool for pathologists is highlighted, while the AI Impact™ in a real-world setting demonstrates the ability of AI to standardize prostate cancer diagnosis at a high level of performance across pathologists.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100378"},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000178/pdfft?md5=9c3ac8cee3a0de7c2dbd11239bf2bccb&pid=1-s2.0-S2153353924000178-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141164206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologists light level preferences using the microscope—study to guide digital pathology display use 病理学家对显微镜光照度的偏好--指导数字病理显示屏使用的研究
Q2 Medicine Pub Date : 2024-04-29 DOI: 10.1016/j.jpi.2024.100379
Charlotte Jennings , Darren Treanor , David Brettle

Background

Currently, there is a paucity of guidelines relating to displays used for digital pathology making procurement decisions, and optimal display configuration, challenging.

Experience suggests pathologists have personal preferences for brightness when using a conventional microscope which we hypothesized could be used as a predictor for display setup.

Methods

We conducted an online survey across six NHS hospitals, totalling 108 practicing pathologists, to capture brightness adjustment habits on both microscopes and displays.

A convenience subsample of respondents was then invited to take part in a practical task to determine microscope brightness and display luminance preferences in the normal working environment. A novel adaptation for a lightmeter was developed to directly measure the light output from the microscope eyepiece.

Results

The survey (response rate 59% n=64) indicates 81% of respondents adjust the brightness on their microscope. In comparison, only 11% report adjusting their digital display. Display adjustments were more likely to be for visual comfort and ambient light compensation rather than for tissue factors, common for microscope adjustments. Part of this discrepancy relates to lack of knowledge of how to adjust displays and lack of guidance on whether this is safe; But, 66% felt that the ability to adjust the light on the display was important.

Twenty consultants took part in the practical brightness assessment. Light preferences on the microscope showed no correlation with display preferences, except where a pathologist has a markedly brighter microscope light preference. All of the preferences in this cohort were for a display luminance of <500 cd/m2, with 90% preferring 350 cd/m2 or less. There was no correlation between these preferences and the ambient lighting in the room.

Conclusions

We conclude that microscope preferences can only be used to predict display luminance requirements where the microscope is being used at very high brightness levels. A display capable of a brightness of 500 cd/m2 should be suitable for almost all pathologists with 300 cd/m2 suitable for the majority. Although display luminance is not frequently changed by users, the ability to do so was felt to be important by the majority of respondents.

Further work needs to be undertaken to establish the relationship between diagnostic performance, luminance preferences, and ambient lighting levels.

背景目前,与数字病理学所用显示器相关的指南很少,这使得采购决定和最佳显示器配置具有挑战性。经验表明,病理学家在使用传统显微镜时对亮度有个人偏好,我们假设这可以用作显示器设置的预测因素。方法我们在六家英国国家医疗服务系统(NHS)医院开展了一项在线调查,共调查了 108 名执业病理学家,以了解他们对显微镜和显示屏亮度的调节习惯,然后邀请方便的受访者子样本参加一项实际任务,以确定他们在正常工作环境中对显微镜亮度和显示屏亮度的偏好。结果调查(回复率为 59% n=64)显示,81% 的受访者会调整显微镜的亮度。相比之下,只有 11% 的受访者表示调整过数字显示屏。显示屏的调整更可能是为了视觉舒适度和环境光补偿,而不是显微镜调整中常见的组织因素。造成这种差异的部分原因是对如何调节显示屏缺乏了解,以及缺乏关于这样做是否安全的指导;但是,66% 的人认为能够调节显示屏上的光线非常重要。对显微镜光线的偏好与对显示屏的偏好没有相关性,除非病理学家对显微镜光线有明显的偏好。该组研究人员的所有偏好都是显示亮度为 500 cd/m2,其中 90% 的人偏好 350 cd/m2 或更低的亮度。结论我们得出结论,只有在显微镜以极高亮度水平使用的情况下,显微镜偏好才可用于预测对显示亮度的要求。亮度为 500 cd/m2 的显示屏几乎适合所有病理学家,而 300 cd/m2 则适合大多数病理学家。虽然用户并不经常改变显示亮度,但大多数受访者认为改变亮度的能力非常重要。
{"title":"Pathologists light level preferences using the microscope—study to guide digital pathology display use","authors":"Charlotte Jennings ,&nbsp;Darren Treanor ,&nbsp;David Brettle","doi":"10.1016/j.jpi.2024.100379","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100379","url":null,"abstract":"<div><h3>Background</h3><p>Currently, there is a paucity of guidelines relating to displays used for digital pathology making procurement decisions, and optimal display configuration, challenging.</p><p>Experience suggests pathologists have personal preferences for brightness when using a conventional microscope which we hypothesized could be used as a predictor for display setup.</p></div><div><h3>Methods</h3><p>We conducted an online survey across six NHS hospitals, totalling 108 practicing pathologists, to capture brightness adjustment habits on both microscopes and displays.</p><p>A convenience subsample of respondents was then invited to take part in a practical task to determine microscope brightness and display luminance preferences in the normal working environment. A novel adaptation for a lightmeter was developed to directly measure the light output from the microscope eyepiece.</p></div><div><h3>Results</h3><p>The survey (response rate 59% <em>n</em>=64) indicates 81% of respondents adjust the brightness on their microscope. In comparison, only 11% report adjusting their digital display. Display adjustments were more likely to be for visual comfort and ambient light compensation rather than for tissue factors, common for microscope adjustments. Part of this discrepancy relates to lack of knowledge of how to adjust displays and lack of guidance on whether this is safe; But, 66% felt that the ability to adjust the light on the display was important.</p><p>Twenty consultants took part in the practical brightness assessment. Light preferences on the microscope showed no correlation with display preferences, except where a pathologist has a markedly brighter microscope light preference. All of the preferences in this cohort were for a display luminance of &lt;500 cd/m<sup>2</sup>, with 90% preferring 350 cd/m<sup>2</sup> or less. There was no correlation between these preferences and the ambient lighting in the room.</p></div><div><h3>Conclusions</h3><p>We conclude that microscope preferences can only be used to predict display luminance requirements where the microscope is being used at very high brightness levels. A display capable of a brightness of 500 cd/m<sup>2</sup> should be suitable for almost all pathologists with 300 cd/m<sup>2</sup> suitable for the majority. Although display luminance is not frequently changed by users, the ability to do so was felt to be important by the majority of respondents.</p><p>Further work needs to be undertaken to establish the relationship between diagnostic performance, luminance preferences, and ambient lighting levels.</p></div>","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100379"},"PeriodicalIF":0.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S215335392400018X/pdfft?md5=0134b221667c45b419ce808d463b9b22&pid=1-s2.0-S215335392400018X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141164205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-algorithm training and validation for identification of endometrial CD138+ cells in infertility-associated conditions; polycystic ovary syndrome (PCOS) and recurrent implantation failure (RIF) 识别不孕症相关病症(多囊卵巢综合征 (PCOS) 和复发性着床失败 (RIF) 中子宫内膜 CD138+ 细胞的人工智能算法训练和验证
Q2 Medicine Pub Date : 2024-04-29 DOI: 10.1016/j.jpi.2024.100380
Seungbaek Lee , Riikka K. Arffman , Elina K. Komsi , Outi Lindgren , Janette A. Kemppainen , Hanna Metsola , Henna-Riikka Rossi , Anne Ahtikoski , Keiu Kask , Merli Saare , Andres Salumets , Terhi T. Piltonen

Background

Endometrial CD138+ plasma cells serve as a diagnostic biomarker for endometrial inflammation, and their elevated occurrence correlates positively with adverse pregnancy outcomes. Infertility-related conditions like polycystic ovary syndrome (PCOS) and recurrent implantation failure (RIF) are closely associated with systemic and local chronic inflammatory status, wherein endometrial CD138+ plasma cell accumulation could also contribute to endometrial pathology. Current methods for quantifying CD138+ cells typically involve laborious and time-consuming microscopic assessments of only a few random areas from a slide. These methods have limitations in accurately representing the entire slide and are susceptible to significant biases arising from intra- and interobserver variations. Implementing artificial intelligence (AI) for CD138+ cell identification could enhance the accuracy, reproducibility, and reliability of analysis.

Methods

Here, an AI algorithm was developed to identify CD138+ plasma cells within endometrial tissue. The AI model comprised two layers of convolutional neural networks (CNNs). CNN1 was trained to segment epithelium and stroma across 28,363 mm2 (2.56 mm2 of epithelium and 24.87 mm2 of stroma), while CNN2 was trained to distinguish stromal cells based on CD138 staining, encompassing 7345 cells in the object layers (6942 CD138− cells and 403 CD138+ cells). The training and performance of the AI model were validated by three experienced pathologists. We collected 193 endometrial tissues from healthy controls (n = 73), women with PCOS (n = 91), and RIF patients (n = 29) and compared the CD138+ cell percentages based on cycle phases, ovulation status, and endometrial receptivity utilizing the AI model.

Results

The AI algorithm consistently and reliably distinguished CD138− and CD138+ cells, with total error rates of 6.32% and 3.23%, respectively. During the training validation, there was a complete agreement between the decisions made by the pathologists and the AI algorithm, while the performance validation demonstrated excellent accuracy between the AI and human evaluation methods (intraclass correlation; 0.76, 95% confidence intervals; 0.36–0.93, p = 0.002) and a positive correlation (Spearman's rank correlation coefficient: 0.79, p < 0.01). In the AI analysis, the AI model revealed higher CD138+ cell percentages in the proliferative phase (PE) endometrium compared to the secretory phase or anovulatory PCOS endometrium, irrespective of PCOS diagnosis. Interestingly, CD138+ percentages differed according to PCOS phenotype in the PE (p = 0.03). On the other hand, the receptivity status had no impact on the cell percentages in RIF samples.

Conclusion

Our findings emphasize the potential and accuracy of the AI algorithm in detecting endometrial

背景子宫内膜 CD138+ 浆细胞是子宫内膜炎症的诊断生物标志物,其发生率升高与不良妊娠结局呈正相关。多囊卵巢综合征(PCOS)和复发性着床失败(RIF)等不孕症相关疾病与全身和局部慢性炎症状态密切相关,而子宫内膜 CD138+ 浆细胞聚集也可能导致子宫内膜病变。目前量化 CD138+ 细胞的方法通常需要在显微镜下对载玻片上的几个随机区域进行费时费力的评估。这些方法在准确反映整个载玻片方面存在局限性,而且容易因观察者内部和观察者之间的差异而产生重大偏差。采用人工智能(AI)进行 CD138+ 细胞鉴定可提高分析的准确性、可重复性和可靠性。人工智能模型由两层卷积神经网络(CNN)组成。CNN1经过训练可分割28,363平方毫米的上皮和基质(2.56平方毫米的上皮和24.87平方毫米的基质),而CNN2经过训练可根据CD138染色区分基质细胞,对象层包括7345个细胞(6942个CD138-细胞和403个CD138+细胞)。三名经验丰富的病理学家对人工智能模型的训练和性能进行了验证。我们收集了来自健康对照组(n = 73)、多囊卵巢综合征妇女(n = 91)和 RIF 患者(n = 29)的 193 份子宫内膜组织,并利用人工智能模型比较了基于周期阶段、排卵状态和子宫内膜接受能力的 CD138+ 细胞百分比。结果人工智能算法能稳定可靠地区分 CD138- 和 CD138+ 细胞,总误差率分别为 6.32% 和 3.23%。在训练验证过程中,病理学家和人工智能算法所做的决定完全一致,而在性能验证中,人工智能和人类评估方法之间的准确性极高(类内相关;0.76,95% 置信区间;0.36-0.93,p = 0.002),且呈正相关(斯皮尔曼等级相关系数:0.79,p <0.01)。在 AI 分析中,AI 模型显示增殖期(PE)子宫内膜的 CD138+ 细胞百分比高于分泌期或无排卵 PCOS 子宫内膜,与 PCOS 诊断无关。有趣的是,PE 中 CD138+ 百分比因 PCOS 表型而异(p = 0.03)。结论我们的研究结果强调了人工智能算法在检测子宫内膜 CD138+ 浆细胞方面的潜力和准确性,与人工检测相比具有明显的优势,如快速分析整张切片图像、减少观察者内部和观察者之间的差异、节省训练有素的专家的宝贵时间以及稳定的生产率。这为应用人工智能技术帮助临床决策提供了支持,例如,在了解子宫内膜周期相位相关动态以及不同生殖疾病方面。
{"title":"AI-algorithm training and validation for identification of endometrial CD138+ cells in infertility-associated conditions; polycystic ovary syndrome (PCOS) and recurrent implantation failure (RIF)","authors":"Seungbaek Lee ,&nbsp;Riikka K. Arffman ,&nbsp;Elina K. Komsi ,&nbsp;Outi Lindgren ,&nbsp;Janette A. Kemppainen ,&nbsp;Hanna Metsola ,&nbsp;Henna-Riikka Rossi ,&nbsp;Anne Ahtikoski ,&nbsp;Keiu Kask ,&nbsp;Merli Saare ,&nbsp;Andres Salumets ,&nbsp;Terhi T. Piltonen","doi":"10.1016/j.jpi.2024.100380","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100380","url":null,"abstract":"<div><h3>Background</h3><p>Endometrial CD138+ plasma cells serve as a diagnostic biomarker for endometrial inflammation, and their elevated occurrence correlates positively with adverse pregnancy outcomes. Infertility-related conditions like polycystic ovary syndrome (PCOS) and recurrent implantation failure (RIF) are closely associated with systemic and local chronic inflammatory status, wherein endometrial CD138+ plasma cell accumulation could also contribute to endometrial pathology. Current methods for quantifying CD138+ cells typically involve laborious and time-consuming microscopic assessments of only a few random areas from a slide. These methods have limitations in accurately representing the entire slide and are susceptible to significant biases arising from intra- and interobserver variations. Implementing artificial intelligence (AI) for CD138+ cell identification could enhance the accuracy, reproducibility, and reliability of analysis.</p></div><div><h3>Methods</h3><p>Here, an AI algorithm was developed to identify CD138+ plasma cells within endometrial tissue. The AI model comprised two layers of convolutional neural networks (CNNs). CNN1 was trained to segment epithelium and stroma across 28,363 mm<sup>2</sup> (2.56 mm<sup>2</sup> of epithelium and 24.87 mm<sup>2</sup> of stroma), while CNN2 was trained to distinguish stromal cells based on CD138 staining, encompassing 7345 cells in the object layers (6942 CD138− cells and 403 CD138+ cells). The training and performance of the AI model were validated by three experienced pathologists. We collected 193 endometrial tissues from healthy controls (<em>n</em> = 73), women with PCOS (<em>n</em> = 91), and RIF patients (<em>n</em> = 29) and compared the CD138+ cell percentages based on cycle phases, ovulation status, and endometrial receptivity utilizing the AI model.</p></div><div><h3>Results</h3><p>The AI algorithm consistently and reliably distinguished CD138− and CD138+ cells, with total error rates of 6.32% and 3.23%, respectively. During the training validation, there was a complete agreement between the decisions made by the pathologists and the AI algorithm, while the performance validation demonstrated excellent accuracy between the AI and human evaluation methods (intraclass correlation; 0.76, 95% confidence intervals; 0.36–0.93, <em>p</em> = 0.002) and a positive correlation (Spearman's rank correlation coefficient: 0.79, <em>p</em> &lt; 0.01). In the AI analysis, the AI model revealed higher CD138+ cell percentages in the proliferative phase (PE) endometrium compared to the secretory phase or anovulatory PCOS endometrium, irrespective of PCOS diagnosis. Interestingly, CD138+ percentages differed according to PCOS phenotype in the PE (<em>p</em> = 0.03). On the other hand, the receptivity status had no impact on the cell percentages in RIF samples.</p></div><div><h3>Conclusion</h3><p>Our findings emphasize the potential and accuracy of the AI algorithm in detecting endometrial ","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100380"},"PeriodicalIF":0.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000191/pdfft?md5=e87bcb34b2122d5de74031fb378126b2&pid=1-s2.0-S2153353924000191-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141084391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the financial aspects of digital pathology: A dynamic customizable return on investment calculator for informed decision-making 了解数字病理学的财务方面:用于知情决策的动态可定制投资回报计算器
Q2 Medicine Pub Date : 2024-04-10 DOI: 10.1016/j.jpi.2024.100376
Orly Ardon , Sylvia L. Asa , Mark C. Lloyd , Giovanni Lujan , Anil Parwani , Juan C. Santa-Rosario , Bryan Van Meter , Jennifer Samboy , Danielle Pirain , Scott Blakely , Matthew G. Hanna

Background

The adoption of digital pathology has transformed the field of pathology, however, the economic impact and cost analysis of implementing digital pathology solutions remain a critical consideration for institutions to justify. Digital pathology implementation requires a thorough evaluation of associated costs and should identify and optimize resource allocation to facilitate informed decision-making. A dynamic cost calculator to estimate the financial implications of deploying digital pathology systems was needed to estimate the financial effects on transitioning to a digital workflow.

Methods

A systematic approach was used to comprehensively assess the various components involved in implementing and maintaining a digital pathology system. This consisted of: (1) identification of key cost categories associated with digital pathology implementation; (2) data collection and analysis of cost estimation; (3) cost categorization and quantification of direct and indirect costs associated with different use cases, allowing customization of each factor based on specific intended uses and market rates, industry standards, and regional variations; (4) opportunities for savings realized by digitization of glass slides and (5) integration of the cost calculator into a unified framework for a holistic view of the financial implications associated with digital pathology implementation. The online tool enables the user to test various scenarios specific to their institution and provides adjustable parameters to assure organization specific relatability.

Results

The Digital Pathology Association has developed a web-based calculator as a companion tool to provide an exhaustive list of the necessary concepts needed when assessing the financial implications of transitioning to a digital pathology system. The dynamic return on investment (ROI) calculator successfully integrated relevant cost and cost-saving components associated with digital pathology implementation and maintenance. Considerations include factors such as digital pathology infrastructure, clinical operations, staffing, hardware and software, information technology, archive and retrieval, medical–legal, and potential reimbursements. The ROI calculator developed for digital pathology workflows offers a comprehensive, customizable tool for institutions to assess their anticipated upfront and ongoing annual costs as they start or expand their digital pathology journey. It also offers cost-savings analysis based on specific user case volume, institutional geographic considerations, and actual costs. In addition, the calculator also serves as a tool to estimate number of required whole slide scanners, scanner throughput, and data storage (TB). This tool is intended to estimate the potential costs and cost savings resulting from the transition to digital pathology for business plan justifications and return on investment calculation

背景数字病理学的采用改变了病理学领域,然而,实施数字病理学解决方案的经济影响和成本分析仍是各机构需要考虑的重要问题。实施数字病理需要对相关成本进行全面评估,并应确定和优化资源分配,以促进知情决策。我们需要一个动态成本计算器来估算部署数字病理系统的财务影响,以估算过渡到数字工作流程的财务影响。我们采用了一种系统方法来全面评估实施和维护数字病理系统所涉及的各个环节。这包括:(1) 确定与数字病理实施相关的关键成本类别;(2) 成本估算的数据收集和分析;(3) 成本分类以及与不同使用案例相关的直接和间接成本量化,允许根据具体的预期用途和市场费率、行业标准以及地区差异对每个因素进行定制;(4) 通过玻璃切片数字化实现节约的机会;(5) 将成本计算器整合到一个统一的框架中,以全面了解与数字病理实施相关的财务影响。数字病理协会开发了一个基于网络的计算器,作为评估过渡到数字病理系统的财务影响所需的必要概念的详尽清单。动态投资回报率(ROI)计算器成功整合了与数字病理实施和维护相关的成本和成本节约要素。考虑因素包括数字病理基础设施、临床操作、人员配备、硬件和软件、信息技术、归档和检索、医疗法律以及潜在报销等。为数字病理工作流程开发的投资回报率计算器提供了一个全面、可定制的工具,供机构在开始或扩展数字病理旅程时评估其预期的前期和持续的年度成本。它还能根据具体用户病例量、机构地理考虑因素和实际成本提供成本节约分析。此外,计算器还可用作估算所需整张玻片扫描仪数量、扫描仪吞吐量和数据存储(TB)的工具。该工具旨在估算向数字病理过渡可能产生的成本和节约的成本,以用于商业计划论证和投资回报计算。结论数字病理在线成本计算器提供了一种全面可靠的方法,用于估算与实施和维护数字病理系统相关的财务影响。该计算器考虑了各种成本因素,并允许根据机构的具体变量进行定制,从而使病理实验室、医疗机构和管理者在采用或扩展数字病理技术时能够做出明智的决策并优化资源分配。投资回报率计算器将使医疗机构能够评估采用数字病理技术的财务可行性和潜在投资回报率,促进知情决策和资源分配。
{"title":"Understanding the financial aspects of digital pathology: A dynamic customizable return on investment calculator for informed decision-making","authors":"Orly Ardon ,&nbsp;Sylvia L. Asa ,&nbsp;Mark C. Lloyd ,&nbsp;Giovanni Lujan ,&nbsp;Anil Parwani ,&nbsp;Juan C. Santa-Rosario ,&nbsp;Bryan Van Meter ,&nbsp;Jennifer Samboy ,&nbsp;Danielle Pirain ,&nbsp;Scott Blakely ,&nbsp;Matthew G. Hanna","doi":"10.1016/j.jpi.2024.100376","DOIUrl":"https://doi.org/10.1016/j.jpi.2024.100376","url":null,"abstract":"<div><h3>Background</h3><p>The adoption of digital pathology has transformed the field of pathology, however, the economic impact and cost analysis of implementing digital pathology solutions remain a critical consideration for institutions to justify. Digital pathology implementation requires a thorough evaluation of associated costs and should identify and optimize resource allocation to facilitate informed decision-making. A dynamic cost calculator to estimate the financial implications of deploying digital pathology systems was needed to estimate the financial effects on transitioning to a digital workflow.</p></div><div><h3>Methods</h3><p>A systematic approach was used to comprehensively assess the various components involved in implementing and maintaining a digital pathology system. This consisted of: (1) identification of key cost categories associated with digital pathology implementation; (2) data collection and analysis of cost estimation; (3) cost categorization and quantification of direct and indirect costs associated with different use cases, allowing customization of each factor based on specific intended uses and market rates, industry standards, and regional variations; (4) opportunities for savings realized by digitization of glass slides and (5) integration of the cost calculator into a unified framework for a holistic view of the financial implications associated with digital pathology implementation. The online tool enables the user to test various scenarios specific to their institution and provides adjustable parameters to assure organization specific relatability.</p></div><div><h3>Results</h3><p>The Digital Pathology Association has developed a web-based calculator as a companion tool to provide an exhaustive list of the necessary concepts needed when assessing the financial implications of transitioning to a digital pathology system. The dynamic return on investment (ROI) calculator successfully integrated relevant cost and cost-saving components associated with digital pathology implementation and maintenance. Considerations include factors such as digital pathology infrastructure, clinical operations, staffing, hardware and software, information technology, archive and retrieval, medical–legal, and potential reimbursements. The ROI calculator developed for digital pathology workflows offers a comprehensive, customizable tool for institutions to assess their anticipated upfront and ongoing annual costs as they start or expand their digital pathology journey. It also offers cost-savings analysis based on specific user case volume, institutional geographic considerations, and actual costs. In addition, the calculator also serves as a tool to estimate number of required whole slide scanners, scanner throughput, and data storage (TB). This tool is intended to estimate the potential costs and cost savings resulting from the transition to digital pathology for business plan justifications and return on investment calculation","PeriodicalId":37769,"journal":{"name":"Journal of Pathology Informatics","volume":"15 ","pages":"Article 100376"},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2153353924000154/pdfft?md5=06d1c9d9fe955e29390f2e8c6402cf66&pid=1-s2.0-S2153353924000154-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140825437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pathology Informatics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1